Abstract: There is provided a radiolabelled peptide-based compound for diagnostic imaging using positron emission tomography (PET). The compound may thus be used for diagnosis of malignant diseases. The compound is particularly useful for imaging of somatostatin overexpression in tumors, wherein the compound is capable of being imaged by PET when administered with a target dose in the range of 150-350 MBq, such as 150-250 MBq, preferable in the range of 191-210 MBq.
Type:
Grant
Filed:
June 27, 2019
Date of Patent:
November 2, 2021
Assignee:
SOMSCAN APS
Inventors:
Andreas Kjaer, Ulrich Knigge, Liselotte Højgaard, Palle Rasmussen
Abstract: There is provided a radiolabelled peptide-based compound for diagnostic imaging using positron emission tomography (PET). The compound may thus be used for diagnosis of malignant diseases. The compound is particularly useful for imaging of somatostatin overexpression in tumors, wherein the compound is capable of being imaged by PET when administered with a target dose in the range of 150-350 MBq, such as 150-250 MBq, preferable in the range of 191-210 MBq.
Type:
Grant
Filed:
November 2, 2018
Date of Patent:
August 20, 2019
Assignee:
SOMSCAN APS
Inventors:
Andreas Kjaer, Ulrich Knigge, Liselotte Højgaard, Palle Rasmussen
Abstract: There is provided a radiolabelled peptide-based compound for diagnostic imaging using positron emission tomography (PET). The compound may thus be used for diagnosis of malignant diseases. The compound is particularly useful for imaging of somatostatin overexpression in tumors, wherein the compound is capable of being imaged by PET when administered with a target dose in the range of 150-350 MBq, such as 150-250 MBq, preferable in the range of 191-210 MBq.
Type:
Grant
Filed:
August 23, 2012
Date of Patent:
December 25, 2018
Assignee:
SOMSCAN APS
Inventors:
Andreas Kjaer, Ulrich Knigge, Liselotte Højgaard, Palle Rasmussen
© 2024 Justia
